Literature DB >> 1637140

Revised estimate of the prevalence of multiple sclerosis in the United States.

D W Anderson1, J H Ellenberg, C M Leventhal, S C Reingold, M Rodriguez, D H Silberberg.   

Abstract

Using three adjustments, we have revised a 1976 prevalence count for multiple sclerosis in the United States. The adjustments were made to data from a US national survey; they used 1990 population projections from the US Bureau of the Census, and results of investigations conducted in Weld and Larimer Countries, Colorado, and Olmsted County, Minnesota. It is estimated that approximately 250,000 to 350,000 persons in the United States in 1990 had physician-diagnosed multiple sclerosis.

Entities:  

Mesh:

Year:  1992        PMID: 1637140     DOI: 10.1002/ana.410310317

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

Review 1.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 2.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

3.  Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients.

Authors:  Amena W Smith; Bently P Doonan; William R Tyor; Nada Abou-Fayssal; Azizul Haque; Naren L Banik
Journal:  J Neuroimmunol       Date:  2010-11-13       Impact factor: 3.478

4.  Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release.

Authors:  E G Vichaya; E E Young; M A Frazier; J L Cook; C J Welsh; M W Meagher
Journal:  J Neuroimmunol       Date:  2011-10-13       Impact factor: 3.478

Review 5.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 6.  Cognitive Assessment of Individuals with Multiple Sclerosis in the Arab World: a Systematic Review.

Authors:  Samira Paul; Aeysha Brown; Abbey J Hughes
Journal:  Neuropsychol Rev       Date:  2019-05-17       Impact factor: 7.444

Review 7.  Neuroimmune interactions in a model of multiple sclerosis.

Authors:  C Jane Welsh; Andrew J Steelman; Wentao Mi; Colin R Young; Ralph Storts; Thomas H Welsh; Mary W Meagher
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

8.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

9.  Longitudinal predictors of attitudes toward aging among women with multiple sclerosis.

Authors:  Tracie Harrison; Shelley Blozis; Alexa Stuifbergen
Journal:  Psychol Aging       Date:  2008-12

Review 10.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.